γ′ fibrinogen: Evaluation of a new assay for study of associations with cardiovascular disease

Clinical Chemistry

Volumn 56, Issue 5, 2010, Pages 781-788

  Lovely, Rehana S ^a   Kazmierczak, Steven C ^b   Massaro, Joseph M ^c   D'Agostino Sr , Ralph B ^d   O'Donnell, Christopher J ^e,f   Farrell, David H ^b  

^a MISSOURI STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d Boston University   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5,5 TETRAMETHYLBENZIDINE; BENZIDINE DERIVATIVE; FIBRINOGEN; HORSERADISH PEROXIDASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2.G2.H9; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHEEP; BLOOD; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; STATISTICAL PARAMETERS; VALIDATION STUDY;

OVIS ARIES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; HUMANS; LIMIT OF DETECTION; MALE; MIDDLE AGED; RISK FACTORS; ROC CURVE;

EID: 77951749933     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.138347     Document Type: Article

References (28)

1. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809 (Pubitemid 41434626)
2. Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol 2007;14:236-241
3. Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008;83:928-931
4. Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of γ chain variants. J Biol Chem 1972;247:5223-5227
5. Chung DW, Davie EW. Gamma and gamma' chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984;23:4232-4236
6. Fornace AJ Jr, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human γ-fibrinogen gene: alternate mRNA splicing near the 3′ end of the gene produces γA and γB forms of γ-fibrinogen. J Biol Chem 1984;259:12826-12830
7. Lovely RS, Falls LA, Al-Mondhiry HA, Chambers CE, Sexton GJ, Ni H, Farrell DH. Association of γA/γ′ fibrinogen levels and coronary artery disease. Thromb Haemost 2002;88:26-31. (Pubitemid 34752262)
8. Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegård A, Farrell DH, et al. Elevated plasma fibrinogen γ′ concentration increases risk of myocardial infarction: effects of genetic variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007;5:766-773 (Pubitemid 46563576)
9. Falls LA, Farrell DH. Resistance of γA/γ′ fibrin clots to fibrinolysis. J Biol Chem 1997;272:14251-14256
10. Collet JP, Nagaswami C, Farrell DH, Montalescot G, Weisel JW. Influence of γ′ fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol 2004;24:382-386 (Pubitemid 38197594)
11. Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing γ′ chains. Blood 2005;106:2730-2736 (Pubitemid 41510747)
12. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996;271:23121-23125 (Pubitemid 26314747)
13. Lovely RS, Moaddel M, Farrell DH. Fibrinogen γ′ chain binds thrombin exosite II. J Thromb Haemost 2003;1:124-131
14. Pospisil CH, Stafford AR, Fredenburgh JC, Weitz, JI. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem 2003;278:21584-21591
15. Sabo TM, Farrell DH, Maurer MC. Conformational analysis of γ′ peptide (410-427) interactions with thrombin anion binding exosite II. Biochemistry 2006;45:7434-7445
16. Pineda AO, Chen ZW, Marino F, Mathews FS, Mosesson MW, Di Cera E. Crystal structure of thrombin in complex with fibrinogen γ′ peptide. Biophys Chem 2007;125:556-559 (Pubitemid 46123760)
17. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant γ′ alters fibrin formation and structure. Blood 2003;102:535-540
18. Gersh KC, Nagaswami C, Weisel JW, Lord ST. The presence of γ′ chain impairs fibrin polymerization. Thromb Res 2009;124:356-363
19. Farrell DH. Pathophysiologic roles of the fibrinogen γ chain. Curr Opin Hematol 2004;11:151-155
20. Uitte de Willige S, Standeven KF, Philippou H, Ariëns RA. The pleiotropic role of the fibrinogen γ′ chain in hemostasis. Blood 2009;114:3994-4001.
21. Cheung EY, Uitte de Willige S, Vos HL, Leebeek FW, Dippel DW, Bertina RM, de Maat MP. Fibrinogen γ′ in ischemic stroke: a case-control study. Stroke 2008;39:1033-1035 (Pubitemid 351619556)
22. Drouet L, Paolucci F, Pasqualini N, Laprade M, Ripoll L, Mazoyer E, et al. Plasma γA/γ′ fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Blood Coag Fibrinolysis 1999;10:S35-9.
23. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979;110:281-290 (Pubitemid 10204328)
24. CLSI. User demonstration of performance for precision and trueness; approved guideline, second edition. CLSI document IP15-A2. CLSI; 2005.
25. Fibrinogen Studies Collaboration, Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies. The Fibrinogen Studies Collaboration. Am J Epidemiol 2007;166:867-879
26. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577 (Pubitemid 23118304)
27. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639
28. Levinson SS. Will CRP actually be useful in assessing risk of cardiovascular disease? Fats of Life Newsletter 2002 Spring;16(2).